Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by analysts at Benchmark to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.
Separately, Cantor Fitzgerald raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, February 25th.
Check Out Our Latest Stock Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- How to Calculate Return on Investment (ROI)
- 5 Reasons the S&P 500 Could Rebound Strongly in 2025
- Stock Splits, Do They Really Impact Investors?
- Best Gold Stocks in 2025… So Far
- With Risk Tolerance, One Size Does Not Fit All
- 5 Reasons Why Halliburton is a Good Buy in 2025
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
